Key result
Transcatheter valve-in-valve implantation with the Edwards SAPIEN valve in high-risk patients with degenerated bioprostheses resulted in 0% 30-day mortality and a 5.6% mortality rate at 11 months.
Why the study?
Is transcatheter valve-in-valve implantation with the Edwards SAPIEN THV feasible and safe in high-risk patients with symptomatic bioprosthetic heart valve failure?
Observational (n=18)
No
Is transcatheter valve-in-valve implantation with the Edwards SAPIEN THV feasible and safe in high-risk patients with symptomatic bioprosthetic heart valve failure?
Transcatheter valve-in-valve implantation with the Edwards SAPIEN THV is a feasible and safe alternative for high-risk patients with degenerated bioprosthetic valves, yielding good periprocedural and mid-term clinical outcomes.
Answers are grounded in this paper and cite their sources.
May support valve-in-valve TAVI in selected high-risk patients; leaves open need for larger prospective studies.
AIMS: Reoperation for bioprosthetic heart valve failure is associated with significant morbidity and mortality, particularly in high-risk patients. Transcatheter valve-in-valve (VIV) implantation may offer a less invasive alternative. The aim of this study was to report our initial experience with transcatheter VIV implantation to treat degenerated tissue valves. METHODS AND RESULTS: VIV implantation with the Edwards SAPIEN transcatheter heart valve (THV; Edwards Lifesciences Inc, Irvine, CA, USA) was performed in 18 high-risk patients (STS 8.2±5.2%; logistic EuroSCORE 37.4±20.8%) with symptomatic bioprosthetic failure (17 aortic, one mitral). Valve Academic Research Consortium (VARC) definitions were applied for endpoint adjudication. Transfemoral access was the preferred vascular approach (16 patients, with the mitral VIV delivered anterogradely through the femoral vein; one transaxillary and one transapical). The majority (83%) of procedures were performed under local anaesthesia and sedation. Device success was achieved in all but one patient who had a final transaortic gradient ≥20mmHg. Acute kidney injury occurred in three patients (Stage 3 in 1), life-threatening or major bleeding in four patients, while major vascular complications occurred in one patient. Permanent pacemaker implantation was required in two patients. There were no deaths or neurological events at 30-day follow-up. At a median follow-up of 11 months (interquartile range 6-16), the mortality rate was 5.6% and all patients were in NYHA class II or lower. CONCLUSIONS: Transcatheter implantation of the Edwards THV within a degenerated aortic bioprosthesis, performed predominantly via the transfemoral route, is feasible and associated with good periprocedural and clinical outcomes in high-risk surgical patients.
No takes yet. Share an insight, caveat, or question.
Latib et al. (2012) conducted an observational in symptomatic bioprosthetic heart valve failure (n=18). Transcatheter valve-in-valve implantation with the Edwards SAPIEN transcatheter heart valve was evaluated on 30-day mortality and neurological events. Transcatheter valve-in-valve implantation with the Edwards SAPIEN valve in high-risk patients with degenerated bioprostheses resulted in 0% 30-day mortality and a 5.6% mortality rate at 11 months.
Synapse has enriched 10 related papers. Consider them for comparative context: